Clinical experience with olanzapine, a new atypical antipsychotic

International Clinical Psychopharmacology

Volumn 13, Issue SUPPL. 1, 1998, Pages

  Wood, Andrew ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Atypical antipsychotic drugs; Extrapyramidal syndromes; Haloperidol; Negative symptoms; Olanzapine; Positive symptoms; Schizophrenia

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO;

APPETITE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYNDROME; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MOOD; MULTICENTER STUDY; NEGATIVE SYNDROME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCHIZOPHRENIA; SEDATION; TARDIVE DYSKINESIA; WEIGHT GAIN; XEROSTOMIA;

EID: 0031906018     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199801001-00010     Document Type: Conference Paper

References (13)

1. American Psychiatric Association (1987). DSM-III-R: Diagnostic and statistical manual of mental disorders. 3rd ed. rev. Washington (DC): American Psychiatric Association.
2. Barnes TR (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
3. Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S (1996a). Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 124:159-167.
4. Beasley CM Jr, Tollefson G, Tran P, et al. (1996b). Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14:111-123.
5. Bymaster FP, Calligaro DO, Falcone JF, et al. (1996). Radio-receptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96.
6. Meltzer HY (1994). An overview of the mechanism of action of clozapine. J Clin Psychiatry 55 (suppl B):47-52.
7. Moore NA, Tye NC, Axton MS, Risius FC (1992). The behavioral pharmacology of olanzapine, a novel 'atypical' antipsychotic agent. J Pharmacol Exp Ther 262:545-551.
8. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 16:1-7.
9. Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA (1996). In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 41:181-186.
10. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatrica Scand 212:11-19.
11. Tollefson GD, Sanger TM (1997). Negative symptoms: a pathanalytic approach to the double-blind, placebo- and haloperidol-controlled clinical trial experience with olanzapine. Am J Psychiatry 154:466-474.
12. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Kreuger JA, Tamura RN, et al. (1997). Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: result of an international collaborative trial. Am J Psychiatry 154:457-465.
13. Tran PV, Hamilton SH, Kuntz AJ, et al. (1997). Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Neuropsychopharmacology 17:407-418.